The demand for rapidly administered, sensitive, and reliable cognitive assessments that are
specifically designed for identifying individuals in the earliest stages of cognitive decline …

Recent evidence indicates that measures from cerebrospinal fluid, MRI scans and cognitive
testing obtained from cognitively normal individuals can be used to predict likelihood of …

Recently published guidelines suggest that the most opportune time to treat individuals with
Alzheimer's disease is during the preclinical phase of the disease. This is a phase when …

Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease
(AD) are required to enable diagnosis of the disease before substantial neurodegeneration …

Mild cognitive impairment (MCI) is a clinical diagnosis in which deficits in cognitive function
are evident but not of sufficient severity to warrant a diagnosis of dementia. For the majority …

The global fight against Alzheimer's disease (AD) poses unique challenges for the field of
neuropsychology. Along with the increased focus on early detection of AD pathophysiology …

The narrow concept of mild cognitive impairment (MCI) as an early form of Alzheimer's
disease has been broadened by research that established the existence of alternative forms …

Introduction We established a method for diagnostic harmonization across multiple studies
of preclinical Alzheimer's disease and validated the method by examining its relationship …

Abstract Introduction Cognitive testing in Alzheimer's disease (AD) is essential for
establishing diagnosis, monitoring progression, and evaluating treatments. Assessments …

Introduction Early identification of Alzheimer's disease (AD) is needed both for clinical trials
and in clinical practice. In this study, we compared brief cognitive tests and cerebrospinal …